Paper42963333PubMed
Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials.
Tariot PN and 15 others. Alzheimers Dement, 2026.
Cite this record
ConductScience Library. Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials. Papers, record 42963333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42963333
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials.
- Journal
- Alzheimers Dement
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Clinical Trials as Topic | Major topic |
| Endpoint Determination | Major topic |
| Communication | Major topic |
| Research Design | Major topic |
| Humans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Bristol Myers Squibb | PubMed |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38561021 | Minimal clinically important difference in Alzheimer's disease: Rapid review. | Alzheimers Dement | 2024 | https://conductscience.org/library/papers/38561021 | PubMed |
| 2 | 35440022 | Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. | Alzheimers Res Ther | 2022 | https://conductscience.org/library/papers/35440022 | PubMed |
| 3 | 12954465 | Responsiveness of goal attainment scaling in a randomized controlled trial of comprehensive geriatric assessment. | J Clin Epidemiol | 2003 | https://conductscience.org/library/papers/12954465 | PubMed |
| 4 | 2691207 | Measurement of health status. Ascertaining the minimal clinically important difference. | Control Clin Trials | 1989 | https://conductscience.org/library/papers/2691207 | PubMed |
| 5 | 11936935 | Methods to explain the clinical significance of health status measures. | Mayo Clin Proc | 2002 | https://conductscience.org/library/papers/11936935 | PubMed |
| 6 | 36763306 | Assessing What Matters to People Affected by Alzheimer's Disease: A Quantitative Analysis. | Neurol Ther | 2023 | https://conductscience.org/library/papers/36763306 | PubMed |
| 7 | 41368997 | Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/41368997 | PubMed |
| 8 | 3337672 | Reliability of the Washington University Clinical Dementia Rating. | Arch Neurol | 1988 | https://conductscience.org/library/papers/3337672 | PubMed |
| 9 | 40463637 | Alzheimer's disease drug development pipeline: 2025. | Alzheimers Dement (N Y) | 2025 | https://conductscience.org/library/papers/40463637 | PubMed |
| 10 | 40225240 | Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression? | Alzheimers Dement (N Y) | 2025 | https://conductscience.org/library/papers/40225240 | PubMed |
| 11 | 38866966 | Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. | Nat Rev Neurol | 2024 | https://conductscience.org/library/papers/38866966 | PubMed |
| 12 | 38706269 | "Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies. | J Prev Alzheimers Dis | 2024 | https://conductscience.org/library/papers/38706269 | PubMed |
| 13 | 30830492 | An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. | J Patient Rep Outcomes | 2019 | https://conductscience.org/library/papers/30830492 | PubMed |
| 14 | 34295959 | Current advances in digital cognitive assessment for preclinical Alzheimer's disease. | Alzheimers Dement (Amst) | 2021 | https://conductscience.org/library/papers/34295959 | PubMed |
| 15 | 37357301 | 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings. | J Prev Alzheimers Dis | 2023 | https://conductscience.org/library/papers/37357301 | PubMed |
| 16 | 40348870 | A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease. | NPJ Digit Med | 2025 | https://conductscience.org/library/papers/40348870 | PubMed |
| 17 | 39350367 | Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force. | J Prev Alzheimers Dis | 2024 | https://conductscience.org/library/papers/39350367 | PubMed |
| 18 | 41330788 | Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. | J Prev Alzheimers Dis | 2026 | https://conductscience.org/library/papers/41330788 | PubMed |
| 19 | 39949872 | Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease. | Alzheimers Dement (N Y) | 2025 | https://conductscience.org/library/papers/39949872 | PubMed |
| 20 | 24886908 | The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. | JAMA Neurol | 2014 | https://conductscience.org/library/papers/24886908 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42963333
GET https://conductscience.org/api/papers/v1/42963333/references?page=2